Stifel Financial Corp Adaptimmune Therapeutics PLC Transaction History

Stifel Financial Corp

  • $99.8 Billion
  • Q2 2025

A detailed history of Stifel Financial Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Stifel Financial Corp holds 23,007 shares of ADAP stock, worth $1,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,007
Previous 26,469 13.08%
Holding current value
$1,150
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$0.22 - $0.32 $761 - $1,107
-3,462 Reduced 13.08%
23,007 $5,000
Q4 2024

Feb 13, 2025
SELL
$0.54 - $0.95 $621 - $1,092
-1,150 Reduced 4.16%
26,469 $14,000
Q2 2024

Aug 13, 2024
BUY
$0.83 - $1.47 $3,172 - $5,618
3,822 Added 16.06%
27,619 $27,000
Q1 2024

May 13, 2024
SELL
$0.7 - $1.75 $2,423 - $6,058
-3,462 Reduced 12.7%
23,797 $37,000
Q4 2023

Feb 12, 2024
SELL
$0.43 - $0.79 $1,106 - $2,033
-2,574 Reduced 8.63%
27,259 $21,000
Q1 2023

May 12, 2023
SELL
$1.06 - $2.16 $901 - $1,836
-850 Reduced 2.77%
29,833 $32,000
Q4 2022

Feb 13, 2023
BUY
$1.05 - $2.53 $1,207 - $2,909
1,150 Added 3.89%
30,683 $44,000
Q3 2022

Nov 14, 2022
SELL
$1.06 - $2.41 $128 - $291
-121 Reduced 0.41%
29,533 $32,000
Q1 2022

May 13, 2022
SELL
$1.73 - $4.06 $14,705 - $34,510
-8,500 Reduced 22.28%
29,654 $61,000
Q4 2021

Feb 14, 2022
SELL
$3.5 - $5.68 $21,150 - $34,324
-6,043 Reduced 13.67%
38,154 $143,000
Q3 2021

Nov 15, 2021
BUY
$3.44 - $6.37 $2,917 - $5,401
848 Added 1.96%
44,197 $229,000
Q2 2021

Aug 13, 2021
BUY
$3.86 - $5.78 $37,580 - $56,274
9,736 Added 28.96%
43,349 $185,000
Q1 2021

May 14, 2021
BUY
$4.9 - $6.83 $14,636 - $20,401
2,987 Added 9.75%
33,613 $178,000
Q4 2020

Feb 12, 2021
SELL
$4.0 - $9.2 $543,356 - $1.25 Million
-135,839 Reduced 81.6%
30,626 $165,000
Q3 2020

Nov 16, 2020
BUY
$7.66 - $10.78 $1.16 Million - $1.63 Million
151,031 Added 978.56%
166,465 $1.33 Million
Q2 2020

Aug 14, 2020
BUY
$2.58 - $12.1 $39,819 - $186,751
15,434 New
15,434 $154,000
Q4 2018

Feb 13, 2019
SELL
$3.76 - $14.16 $341,618 - $1.29 Million
-90,856 Closed
0 $0
Q3 2018

Nov 13, 2018
BUY
$8.27 - $13.56 $751,379 - $1.23 Million
90,856 New
90,856 $1.22 Million

Others Institutions Holding ADAP

# of Institutions
68
Shares Held
116M
Call Options Held
10.3K
Put Options Held
0
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $8.17M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email